Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

6.270 -0.320 (-4.86%)
Streaming Delayed Price Updated: 11:06 AM EST, Feb 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
News headline image
Could Psilocybin Be A Game-Changer For Millions Battling Depression? New Study Says Yes ↗
Over 5 million Americans with depression could be eligible for psilocybin-assisted therapy if FDA-approved, signaling vast market potential. 
Via Benzinga
News headline image
Psilocybin Breakthrough: Study Reveals Potential Application For Body Dysmorphic Disorder ↗
New study suggests psilocybin may help treat body dysmorphic disorder by rewiring brain connectivity and reducing obsessive thought patterns. 
Via Benzinga
News headline image
Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit
From Compass Pathfinder Limited
Via Business Wire
News headline image
Psychedelic Drug Stocks +6% Last Week Vs. -13% Previous Week ↗
The psychedelic compound-based drug market is expected to triple over the next few years, creating many winning stocks in the years to come. 
Via Talk Markets
News headline image
MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward? ↗
 
Via Benzinga
News headline image
Psychedelic Compound-Based Drug Stocks Portfolio -13% W/e Sept. 6th ↗
While the psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come, the stocks of the companies involved are... 
Via Talk Markets
News headline image
Our Psychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16% In August ↗
The psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come and, to monitor their progress we present a... 
Via Talk Markets
News headline image
Shake Up At Lykos Therapeutics After FDA Blocks Ecstasy-Based Treatment, CEO Steps Down ↗
Lykos Therapeutics CEO Amy Emerson steps down following the FDA's rejection of the company's MDMA-based PTSD therapy. 
Via Benzinga
News headline image
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration ↗
The global psychedelic drugs market is projected to grow by USD 1.37 billion by 2028, driven by mental health needs and AI advancements in drug development. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Largest Psychedelic Compound -Based Clinical-Stage Drug Stocks Up 6% Last Week ↗
Opportunities to invest in psychedelic stocks are emerging for those willing to get in early, and the 4 largest psychedelic compound-based portfolio drug discovery companies are up 5.9% in the past... 
Via Talk Markets
News headline image
Psychedelic Compound-Based Drug Stocks Portfolio: Up 17.5% In July; Down 19% MTD ↗
This article highlights the 4 largest market cap clinical-stage psychedelic compound-based drug discovery companies with their stock performances MTD, in July, their areas of focus, and their latest... 
Via Talk Markets
News headline image
Compass Pathways Plc (CMPS) Q2 2024 Earnings Call Transcript ↗
CMPS earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves ↗
Jamaica introduces its first legal psilocybin products in pharmacies through a historic partnership between PATOO and Fontana Pharmacy. 
Via Benzinga
News headline image
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD ↗
The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,... 
Via Talk Markets
News headline image
3 Dirt-Cheap Drug Developers With Blockbuster Potential ↗
These are three of the best cheap drug developer stocks for investors to keep an eye as their growth could be imminent. 
Via InvestorPlace
News headline image
3 Next-Gen Drug Stocks Exploring Psychedelic Frontiers ↗
These psychedelic drug stocks aren't as radical as once thought as institutional awareness and emphasize on their potential increases. 
Via InvestorPlace
News headline image
3 Psychedelic Stocks to Buy on the Dip: Summer 2024 ↗
These are three of the best psychedelic stocks to buy on the dip for potentially lucrative future growth and returns. 
Via InvestorPlace
News headline image
Largest Clinical-Stage BioTech Drug Stocks Declined 6% ↗
Of the 10 clinical-stage AI-focused and psychedelic compound-based small cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced this week. On average they... 
Via Talk Markets
News headline image
Should You Buy the Dip on Compass Pathways Stock? ↗
Nothing is going wrong, but one of its peers just hit a serious snag. 
Via The Motley Fool
News headline image
Psychedelics Stocks Are Falling After a Shocking Vote at the FDA. Here's What You Need to Know. ↗
Regulators were not impressed by one company's petition for approval. 
Via The Motley Fool
News headline image
Largest Psychedelic Compound Based Drug Stocks Fell 13% Last Week - Here's Why ↗
Stocks for companies developing psychedelic treatments fell last Wednesday after advisers to the Food and Drug Administration voted against a mental-health therapy using the drug MDMA. 
Via Talk Markets
News headline image
Why Lands' End Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
What's Going On With MindMed And Psychedelic Stocks? ↗
Mind Medicine (MindMed) shares are trading lower Wednesday after a Food and Drug Administration (FDA) panel rejected the approval of MDMA therapy for people with post-traumatic stress disorder (PTSD).... 
Via Benzinga
News headline image
DouYu International Posts Q1 Results, Joins Annexon, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Stitch Fix Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
GSK, Boston Beer And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
These 2 Catalysts Could Soon Send Compass Pathways Stock Soaring ↗
Psychedelic medicines are rapidly gaining legitimacy on several fronts. 
Via The Motley Fool
News headline image
Pot Company Gets License To Open Psilocybin Service Center, The Sacred Mushroom, In Oregon ↗
 
Via Benzinga
Topics Cannabis
< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.